crohn's disease and glp-1 Agonists Disease: Risks and Management Recommendations for the safe and
Description
2020;105:e2695e2709
There's now a pill but does it actually work
Cardiovascular protection stands as another major benefit unrelated to weight loss
Deacon CF, Nauck MA, ToftNielsen M, Pridal L, Willms B, Holst JJ
Effect of glepaglutide, a long-acting glucagon-like peptide-2 analog, on gastrointestinal transit time and motility in patients with short bowel syndrome: findings from a randomized trial
